Publications
Selected Publications
Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care. J Gen Intern Med 2012
Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR. Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. HIV Clin Trials 2012;13:1-10.
Schackman BR, Leff JA, Botsko M, Fiellin DA, Altice FL, Korthuis PT, Sohler N, Weiss L, Egan JE, Netherland J, Gass J, Finkelstein R, Bhives Collaborative. The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation. J Acquir Immune Defic Syndr 2011;56 Suppl 1:S76-82.
Koenig SP, Bang H, Severe P, Jean Juste MA, Ambroise A, Edwards A, Hippolyte J, Fitzgerald DW, McGreevy J, Riviere C, Marcelin S, Secours R, Johnson WD, Pape JW, Schackman BR. Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti. PLoS Med 2011;8:e1001095.
Haynes LF, Korte JE, Holmes BE, Gooden L, Matheson T, Feaster DJ, Leff JA, Wilson L, Metsch LR, Schackman BR. HIV rapid testing in substance abuse treatment: Implementation following a clinical trial. Eval Program Plann 2011;34:399-406.
Schackman BR. Implementation science for the prevention and treatment of HIV/AIDS. J Acquir Immune Defic Syndr. 2010 Dec 1;55 Suppl 1:S27-31.
Martin EG, Paltiel AD, Walensky RP, Schackman BR. Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis. Value Health. 2010 Dec;13(8):893-902.
Schackman BR, Dastur Z, Rubin DS, Berger J, Camhi E, Netherland J, Ni Q, Finkelstein R. Feasibility of using audio computer-assisted self-interview (ACASI) screening in routine HIV care. AIDS Care. 2009 Aug;21(8):992-9.
Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for UGT1A1 before irinotecan administration for metastatic colorectal cancer. Cancer. 2009; 115:3858-67.
Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008; 22:2025-33.
Teixeira PA, Schackman BR. Can urban methadone patients complete health utility assessments? Patient Educ Couns . 2008; 71:302-7.
Schackman BR, Teixeira PA, Weitzman G, Mushlin AI, Jacobson IM. Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree? Med Decis Making. 2008; 28:233-242.
Koenig SP, Riviere C, Leger P, Severe P, Atwood S, Fitzgerald D, Pape JW, Schackman BR. The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc 2008; 6:3.
Schackman BR, Dastur Z, Ni Q, Callahan M, Berger J, Rubin DS. Sexually active HIV patients frequently report never using condoms in audio computer-assisted self-Interviews conducted at routine clinical visits. AIDS Patient Care STDS. 2008; 22:123-129.
Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr. 2007; 46:547-554.
Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, McKinnon JE, Swindells S, Weinstein MC, Freedberg KA. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis. 2007; 45:1062-70.
Schackman, BR, Teixeira PA, Beeder AB. Offers of hepatitis C care do not lead to treatment. J. Urban Health 2007; 84:455-8.
Schackman, BR, Neukermans, CP, Nerette Fontain, SN, Nolte, C, Jospeph P, Pape, JW, Fitzgerald DW. Cost-effectiveness of rapid syphilis screening in prenatal HIV testing programs in Haiti. PLoS Medicine 2007;4:e183.
Schackman BR, Merrill JO, McCarty D, Levi J, Lubinsky C. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis 2006; 43:S247-53.
Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore R, Freedberg KA. The lifetime cost of current HIV care in the United States. Med Care 2006; 44: 990-97
Schackman BR, Finkelstein R, Neukermans CP, Lewis L, Eldred L, for the Center for Adherence Support and Evaluation (CASE) team. The cost of HIV medication adherence support interventions: results of a cross-site evaluation. AIDS Care. 2005; 17:927-937.
Schackman BR, Freedberg KA, Goldie SJ, Weinstein MC, Swartz K. Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment in Georgia and Massachusetts. Health Care Financ Rev. 2005; 26:67-80.
Schackman BR, Oneda K, Goldie SG. The cost-effectiveness of elective cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women. AIDS. 2004;18:1827-34.
Schackman BR, Gold HT, Stone PW, Neumann PJ. How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions? PharmacoEconomics 2004;22:293-300.
Schackman BR, Freedberg KA, Weinstein MC, Sax P, Zang H, Goldie SJ. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002;162:2478-2486.
Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. A comparison of health state utilities using community and patient preference weights derived from a survey of HIV/AIDS patients. Med Decis Making. 2002; 22:27-38.
Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Publ Health 2001;91:1456-63.
